Effect of SCH 23390 on (±)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 4, 2004, Pages 745-750

  Daniela, Evangelene ^a   Brennan, Katie ^a   Gittings, Dave ^a   Hely, Lincoln ^a   Schenk, Susan ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Dopamine; Hyperactivity; MDMA; SCH 23390; Self administration

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; DRUG SELF ADMINISTRATION; HYPERACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERKINESIS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION;

RATTUS NORVEGICUS;

EID: 1942519843     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.01.008     Document Type: Article

References (72)

1. Baker L.E., Makhay M.M. Effects of (+)-fenfluramine on 3,4-methylenedioxymethamphetamine (MDMA) discrimination in rats. Pharmacol. Biochem. Behav. 53:1996;455-461.
2. Bankson M.G., Cunningham K.A. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interaction. J. Pharmacol. Exp. Ther. 297:2001;846-852.
3. Bankson M.G., Cunningham K.A. Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT1b/1d and 5-HT2 receptors. Neuropsychopharmacology. 26:2002;40-52.
4. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 149:1988;159-163.
5. Beardsley P.M., Balster R.L., Harris L.S. Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend. 18:1986;149-157.
6. Beninger R.J., Miller R. Dopamine D1-like receptors and reward-related incentive learning. Neurosci. Biobehav. Rev. 22:1988;335-345.
7. Benniger R.J., Hoffman D.C., Mazurski E.L. Receptor subtypes-specific dopaminergic agents and conditioned behavior. Neurosci. Biobehav. Rev. 13:1989;113-122.
8. Bergman J., Kaimen J.B., Spealman R.D. Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav. Pharmacol. 1:1990;355-363.
9. Bilsky E.J., Reid L.D. MDL72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. Pharmacol. Biochem. Behav. 39:1991;509-512.
10. Blackburn T.P., Minabe Y., Middlemiss D.N., Shirayama Y., Hashimoto K., Ashby C.R. Jr. Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse. 46:2002;129-139.
11. Bonaccorso S., Meltzer H.Y., Li Z., Dai J., Alboszta A.R., Ichikawa J. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 27:2002;430-441.
12. Braida D., Sala M. Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br. J. Pharmacol. 136:2002;1089-1092.
13. Caine S.B., Koob G.F. Effects of dopamine D1 and D2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J. Pharmacol. Exp. Ther. 270:1994;209-218.
14. Callaway C.W., Geyer M.A. Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist. J. Pharmacol. Exp. Ther. 263:1992;318-326.
15. Callaway C.W., Wing L.L., Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J. Pharmacol. Exp. Ther. 254:1990;456-464.
16. Cole J.C., Sumnall H.R. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci. Biobehav. Rev. 27:2003;199-217.
17. Cole J.C., Sumnall H.R., O'Shea E., Marsden C.A. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology. 166:2003;383-390.
18. Corrigall W.A., Coen K.M. Cocaine self-administration is increased by both D1 and D2 dopamine antagonists. Pharmacol. Biochem. Behav. 39:1991;799-802.
19. Corrigall W.A., Vaccarino F.J. Antagonist treatment in nucleus accumbens or periaqueductal grey affects heroin self-administration. Pharmacol. Biochem. Behav. 30:1988;443-450.
20. Cottler L.B., Womack S.B., Compton W.M., Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum. Psychopharmacol. 16:2001;599-606.
21. Czoty P.W., Ginsburg B.C., Howell L.L. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J. Pharmacol. Exp. Ther. 300:2002;831-837.
22. Deneau G., Yanagita T., Seevers M.H. Self-administration of psychoactive substances by the monkey. Psychopharmacologia. 16:1969;30-48.
23. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur. J. Pharmacol. 375:1999;13-30.
24. Di Giovanni G., Di Matteo V., Di Mascio M., Esposito E. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse. 35:2000;53-61.
25. Dworkin S., Guerin G., Co C., Smith J., Goeder N. Effects of 5,7-dihydroxytryptamine lesions of the nucleus accumbens in rats responding on a concurrent schedule of food, water and intravenous morphine self-administration. NIDA Res. Monogr. 81:1988;149-155.
26. Fantegrossi W.E., Ullrich T., Rice K.C., Woods J.H., Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology. 161:2002;356-364.
27. Filip M., Cunningham K.A. Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin2C (5-HT2C) receptors in rat prefrontal cortex. J. Pharmacol. Exp. Ther. 306:2002;734-743.
28. Fletcher P.J., Robinson S.R., Slippoy D.L. Pre-exposure to (+-)3,4-methylenedioxymethamphetamine (MDMA) facilitates acquisition of intravenous cocaine self-administration in rats. Neuropsychopharmacology. 25:2001;195-203.
29. Fletcher P.J., Grottick A.J., Higgins G.A. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology. 27:2002;576-586.
30. Fletcher P.J., Korth K.M., Robinson S.R., Baker G.B. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology. 162:2002;282-291.
31. Gold L.H., Hubner C.B., Koob G.F. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology. 99:1989;40-47.
32. Griffiths R.R., Bigelow G.R., Liebson I. Experimental drug self-administration: generality across species and type of drug. NIDA Res. Monogr. 20:1978;24-44.
33. Gudelsky G.A., Yamamoto B.K., Nash J.F. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur. J. Pharmacol. 264:1994;325-330.
34. Hanson H.M., Ivester C.A., Morton B.R. Nicotine self-administration in rats. NIDA Res. Monogr. 23:1979;70-90.
35. Hubner C.B., Moreton J.E. Effects of selective D1 and D2 dopamine antagonists on cocaine self-administration in the rat. Psychopharmacology. 105:1991;151-156.
36. Iravani M.M., Asari D., Patel J., Wieczorek W.J., Kruk Z.L. Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse. 36:2000;275-285.
37. Itzhak Y., Ali S.F., Achat C.N., Andersen K.L. Relevance of MDMA ("ecstasy")-induced neurotoxicity to long lasting psychomotor stimulation in mice. Psychopharmacology. 166:2003;241-248.
38. Kalivas P.W., Duffy P., White S.R. MDMA elicits behavioural and neurochemical sensitization in rats. Neuropsychopharmacology. 18:1998;469-479.
39. Kehne J.H., Kettler H.J., McCloskey T.C., Sullivan C.K., Dudley M.W., Schmidt C.J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology. 15:1996;116-124.
40. Koch S., Galloway M.P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural Transm. 104:1997;135-146.
41. Koob G.F., Pettit H.O., Ettenberg A., Bloom F.E. Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat. J. Pharmacol. Exp. Ther. 229:1984;481-486.
42. Koob G.F., Le H.T., Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci. Lett. 79:1987;315-320.
43. Lamb R.J., Griffiths R.R. Self-injection of d,1-3,4- methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology. 91:1987;268-272.
44. Leccese A.P., Lyness W.H. The effects of putative 5-hydroxytryptamine receptor active agents on D-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions. Brain Res. 303:1984;153-162.
45. Liechti M.E., Vollenweider F.X. Acute psychological and physiological effects of MDMA ("ecstasy") after haloperidol pretreatment in healthy humans. Eur. Neuropsychopharmacol. 10:2000;289-295.
46. Loh E.A., Roberts D.C. Break-points on a progressive ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. Psychopharmacology. 101:1990;262-266.
47. McCreary A.C., Bankson M.G., Cunningham K.A. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/ 1D) receptors. J. Pharmacol. Exp. Ther. 290:1999;965-973.
48. McGregor I.S., Clemens K.J., Van Der Plasse G., Li K.M., Hunt G.E., Chen F.et al. Increased anxiety 3 months after brief exposure to MDMA ('ecstasy') in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology. 28:2003;1472-1484.
49. Meyer M.E., Cottrell G.A., Van Hartesveldt C., Potter T.J. Effects of dopamine D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats. Pharmacol. Biochem. Behav. 44:1993;429-432.
50. Millan M.J., Newman-Tancredi A., Quentric Y., Cussac D. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology. 156:2001;58-62.
51. Morgan A.E., Horan B., Dewey S.L., Ashby C.R. Jr. Repeated administration of 3,4-methylenedioxymethamphetamine augments cocaine's action on dopamine in the nucleus accumbens: a microdialysis study. Eur. J. Pharmacol. 331:1997;R1-R3.
52. Nash J.F., Brodkin J. Microdialysis studies on 3,4- methylenedioxymehtamphetmine-induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 259:1991;820-825.
53. Nichols D.E., Brewster W.K., Johnson M.P., Oberlender R., Riggs R.M. Non-neurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem. 33:1990;703-710.
54. Obradovic T., Imel K.M., White S.R. Methylenedioxymethamphetamine-induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine. Neuroscience. 74:1996;469-481.
55. Phillips G.D., Robbins T.W., Everitt B.J. Bilateral intra-accumbens self-administration of D-amphetamine: antagonism with intra-accumbens SCH 23390 and sulpiride. Psychopharmacology. 114:1994;477-485.
56. Piggins H., Merali Z. The effects of concurrent D-1 and D-2 dopamine receptor blockade with SCH 23390 and eticlopride, on bombesin-induced behaviours. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 13:1989;583-594.
57. Pilotto R., Singer G., Overstreet D. Self-injection of diazepam in naive rats: effects of dose, schedule and blockade of different receptors. Psychopharmacology. 84:1984;174-177.
58. Ratzenboeck E., Saria A., Kreichbaum N., Zernig G. Reinforcing effects of MDMA ('ecstasy') in drug-naïve and cocaine-trained rats. Pharmacology. 62:2001;138-144.
59. Reneman L., Lavalaye J., Schmand B., De Wolff F.A., Van den Brink W., Den Heeten G.J.et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch. Gen. Psychiatry. 58:2001;901-906.
60. Ricaurte G.A., Yuan J., McCann U. (±)3,4- Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology. 42:2000;5-10.
61. Scearce-Levie K., Viswanathan S.S., Hen R. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology. 141:1999;154-161.
62. Schechter M.D. Effect of serotonin depletion by p-chlorophenylalanine upon discriminative behaviours. Gen. Pharmacol. 22:1991;889-893.
63. Schenk S., Gittings D., Jonson M., Daniela E. Development, maintenance and temporal pattern maintained by MDMA self-administration in rats. Psychopharmacology. 169:2003;21-27.
64. Schenk S., Flanagan J., Pablo J.P., Mash D. Down-regulation of serotonin transporters in MDMA self-administrating rats: implications for the consequences of human MDMA use. Society for Neuroscience Abstracts. 2003;135.4.
65. Schmidt C.J., Kehne J.H. Neurotoxicity of MDMA: neurochemical effects. Ann. N. Y. Acad. Sci. 600:1990;665-681.
66. Schmidt C.J., Sullivan C.K., Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62:1994;1382-1389.
67. Schuster C.R., Thompson T. Self administration of and behavioural dependence on drugs. Annu. Rev. Pharmacol. 9:1969;483-502.
68. Spealman R.D., Goldberg S.R. Drug self-administration by laboratory animals: control by schedules of reinforcement. Annu. Rev. Pharmacol. Toxicol. 18:1978;313-339.
69. Watkins S.S., Epping-Jordan M.P., Koob G.F., Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol. Biochem. Behav. 62:1999;743-751.
70. White S.R., Obradovic T., Imel K.M., Wheaton M.J. The effects of methylenedioxymethamphetamine (MDMA, 'ecstasy') on monoaminergic neurotransmission in the central nervous system. Prog. Neurobiol. 49:1996;455-479.
71. Yamamoto B.K., Spanos L.J. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur. J. Pharmacol. 148:1988;195-203.
72. Yokel R.A., Wise R.A. Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology. 48:1976;311-318.